New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01)
Post Date
August 7th 2014
Application Due Date
July 8th 2015
Funding Opportunity Number
PAR-14-314
CFDA Number(s)
93.396
Funding Instrument Type(s)
Cooperative Agreement
Funding Activity Categories
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Funding
-
Award Range:
$None - $750000
Grant Description
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for projects to identify targets whose inhibition would induce synthetic lethality in cancers dependent on the expression of mutant KRas alleles. Despite recent advances in understanding the structural and biological complexities of mutant Ras proteins, the development of appropriate and effective methods to inhibit mutant Ras-dependent cancers has been hindered by the inability to directly target mutant Ras and the complexity of Ras processing, effector, and regulatory networks. Through this FOA, the NCI seeks to stimulate research that uses advanced or improved approaches for synthetic lethality screens that have greater specificity, reproducibility, and activity in physiologically relevant model systems than those used previously in first generation screening approaches. This FOA serves to engage extramural investigators in the mission of the NCI Frederick National Laboratory for Cancer Research (FNLCR) RAS Program to find ways to target Ras-dependent cancers. Investigators supported by this FOA will form a network to interact closely with the FNLCR RAS Program, actively exchange results across the network, and participate in cross-validation of potential targets identified by other awardees.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: